InMed Pharmaceuticals Inc. Files 2024 Annual Report

TL;DR

InMed Pharma filed its 2024 10-K. Check financials and biz ops.

AI Summary

InMed Pharmaceuticals Inc. filed its annual report for the fiscal year ended June 30, 2024. The company, incorporated in British Columbia, Canada, operates in the pharmaceutical preparations sector. Its principal executive office is located at 1445, 885 West Georgia St., Vancouver, B.C., Canada. The filing details the company's operations and financial status for the reporting period.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of InMed Pharmaceuticals Inc.'s financial performance, business operations, and risk factors for the fiscal year ending June 30, 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, InMed Pharmaceuticals Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Players & Entities

• InMed Pharmaceuticals Inc. (company) — Registrant
• June 30, 2024 (date) — Fiscal year end
• Vancouver, B.C., Canada (location) — Principal executive office location
• 001-39685 (other) — Commission file number

FAQ

Filing Documents

• ea0214241-10k_inmed.htm (10-K) — 1360KB
• ea021424101ex4-13_inmed.htm (EX-4.13) — 8KB
• ea021424101ex10-19_inmed.htm (EX-10.19) — 155KB
• ea021424101ex10-20_inmed.htm (EX-10.20) — 115KB
• ea021424101ex21-1_inmed.htm (EX-21.1) — 3KB
• ea021424101ex23-1_inmed.htm (EX-23.1) — 2KB
• ea021424101ex31-1_inmed.htm (EX-31.1) — 12KB
• ea021424101ex31-2_inmed.htm (EX-31.2) — 12KB
• ea021424101ex32-1_inmed.htm (EX-32.1) — 4KB
• ea021424101ex32-2_inmed.htm (EX-32.2) — 4KB
• ea021424101ex97-1_inmed.htm (EX-97.1) — 41KB
• image_001.jpg (GRAPHIC) — 32KB
• image_002.jpg (GRAPHIC) — 67KB
• image_003.jpg (GRAPHIC) — 93KB
• image_004.jpg (GRAPHIC) — 20KB
• image_005.jpg (GRAPHIC) — 81KB
• image_006.jpg (GRAPHIC) — 20KB
• image_007.jpg (GRAPHIC) — 4KB
• 0001213900-24-082843.txt ( ) — 7291KB
• inm-20240630.xsd (EX-101.SCH) — 50KB
• inm-20240630_cal.xml (EX-101.CAL) — 47KB
• inm-20240630_def.xml (EX-101.DEF) — 257KB
• inm-20240630_lab.xml (EX-101.LAB) — 482KB
• inm-20240630_pre.xml (EX-101.PRE) — 271KB
• ea0214241-10k_inmed_htm.xml (XML) — 551KB

Risk Factors

Risk Factors 25 Item 1B. Unresolved Staff Comments 65 Item 1C. Cybersecurity 65 Item 2.

Properties

Properties 66 Item 3.

Legal Proceedings

Legal Proceedings 66 Item 4. Mine Safety Disclosures 66 Part II 67 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 67 Item 6. [Reserved] 67 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 67 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 78 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 79 Item 9A.

Controls and Procedures

Controls and Procedures 79 Item 9B. Other Information 80 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevents Inspections 80 Part III 81 Item 10. Directors, Executive Officers and Corporate Governance 81 Item 11.

Executive Compensation

Executive Compensation 81 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 81 Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accounting Fees and Services 81 Part IV 82 Item 15. Exhibits and Financial Statement Schedules 82 Item 16. 10-K Summary 83

Signatures

Signatures 84 i PART I Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K (this "Annual Report") contains "forward-looking statements" within the meaning of United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities law, which are included but are not limited to statements with respect to InMed Pharmaceuticals Inc.'s (the "Company" "InMed", "we", "our", or "us") anticipated results and progress of the Company's operations, research and development in future periods, plans related to its business strategy, and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We may, in some cases, use words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will", "would", "budget", "possible", "should", "future", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. These forward-looking You should not place undue reliance on these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking 1A. Risk Factors " of this Annual Report, "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations " of this Annual Report, and the following: The Company's ability to stem operating

View Full Filing

View this 10-K filing on SEC EDGAR